Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

Nature Communications

Volumn 7, Issue , 2016, Pages

  Chen, Qian ^a   Xu, Ligeng ^a   Liang, Chao ^a   Wang, Chao ^a   Peng, Rui ^a   Liu, Zhuang ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMIQUIMOD; INDOCYANINE GREEN; POLYGLACTIN; 1-(2-METHYLPROPYL)-1H-IMIDAZO(4,5-C)QUINOLIN 4-AMINE; IMMUNOLOGICAL ADJUVANT; LACTIC ACID; MONOCLONAL ANTIBODY; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; QUINOLINE DERIVATIVE;

ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; IMMUNE SYSTEM; MEMORY; NANOPARTICLE; RODENT; TUMOR; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOSTIMULATION; METASTASIS INHIBITION; MOUSE; NANOENCAPSULATION; NONHUMAN; PHOTOTHERMAL THERAPY; PRIMARY TUMOR; TUMOR ABLATION; TUMOR RECURRENCE; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CHEMISTRY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PHOTOTHERAPY; PROCEDURES; TUMOR CELL LINE;

MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELLS, CULTURED; CTLA-4 ANTIGEN; FEMALE; IMMUNE SYSTEM; IMMUNOTHERAPY; INDOCYANINE GREEN; LACTIC ACID; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PHOTOTHERAPY; POLYGLYCOLIC ACID; QUINOLINES;

EID: 84992426115     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13193     Document Type: Article

References (67)

1. Hamdy, S., Haddadi, A., Hung, R. W., Lavasanifar, A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug Deliv. Rev. 63, 943-955 (2011).
2. Sheng, W.-Y., Huang, L. Cancer immunotherapy and nanomedicine. Pharm. Res. 28, 200-214 (2011).
3. Matsuo, Y., Takeyama, H., Guha, S. Cytokine network: new targeted therapy for pancreatic cancer. Curr. Pharm. Des. 18, 2416-2419 (2012).
4. Zhang, G. R., Li, W., Holle, L., Chen, N. Y., Chen, W. Y. A novel design of targeted endocrine and cytokine therapy for breast cancer. Clin. Cancer Res. 8, 1196-1205 (2002).
5. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
6. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
7. Curran, K. J., Brentjens, R. J. Chimeric antigen receptor T cells for cancer immunotherapy. J. Clin. Oncol. 33, 1703-1706 (2015).
8. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. New Engl. J. Med. 371, 1507-1517 (2014).
9. Kalos, M., June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49-60 (2013).
10. Restifo, N. P., Dudley, M. E., Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269-281 (2012).
11. Gattinoni, L., Powell, D. J., Rosenberg, S. A., Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6, 383-393 (2006).
12. Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808 (2015).
13. Palucka, K., Banchereau, J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12, 265-277 (2012).
14. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
15. Ledford, H. Immunotherapy's cancer remit widens. Nature 497, 544-544 (2013).
16. Ledford, H. Therapeutic cancer vaccine survives biotech bust. Nature 519, 17-18 (2015).
17. DeFrancesco, L. CAR-T cell therapy seeks strategies to harness cytokine storm. Nat. Biotechnol. 32, 604-604 (2014).
18. Fang, R. H. et al. Cancer cell membrane-coated nanoparticles for anticancer vaccination and drug delivery. Nano Lett. 14, 2181-2188 (2014).
19. Chen, W., Yan, W., Huang, L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother. 57, 517-530 (2008).
20. Rosenberg, S. A., Yang, J. C., Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10, 909-915 (2004).
21. Finn, O. J. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3, 630-641 (2003).
22. Lollini, P. L., Cavallo, F., Nanni, P., Forni, G. Vaccines for tumour prevention. Nat. Rev. Cancer 6, 204-216 (2006).
23. Lee, P. P. et al. Characterization of circulating T cells specific for tumorassociated antigens in melanoma patients. Nat. Med. 5, 677-685 (1999).
24. Hakomori, S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. 491, 369-402 (2001).
25. Brinkman, J. A., Fausch, S. C., Weber, J. S., Kast, W. M. Peptide-based vaccines for cancer immunotherapy. Expert Opin. Biol. Ther. 4, 181-198 (2004).
26. Cicchelero, L., de Rooster, H., Sanders, N. N. Various ways to improve whole cancer cell vaccines. Expert Rev. Vaccines 13, 721-735 (2014).
27. Cheng, L., Wang, C., Feng, L. Z., Yang, K., Liu, Z. Functional nanomaterials for phototherapies of cancer. Chem. Rev. 114, 10869-10939 (2014).
28. Sherlock, S. P., Tabakman, S. M., Xie, L., Dai, H. Photothermally enhanced drug delivery by ultrasmall multifunctional FeCo/graphitic shell nanocrystals. ACS Nano 5, 1505-1512 (2011).
29. Tao, Y., Ju, E. G., Ren, J. S., Qu, X. G. Immunostimulatory oligonucleotidesloaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy. Biomaterials 35, 9963-9971 (2014).
30. Guo, L. R. et al. Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano 8, 5670-5681 (2014).
31. Kostarelos, K., Bianco, A., Prato, M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat. Nanotechnol. 4, 627-633 (2009).
32. Li, X. et al. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients A preliminary study. Cancer Biol. Ther. 10, 1081-1087 (2010).
33. Zhou, F. F. et al. Antitumor immunologically modified carbon nanotubes for photothermal therapy. Biomaterials 33, 3235-3242 (2012).
34. Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-550 (2011).
35. Le Mercier, I. et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73, 4629-4640 (2013).
36. Janeway, C. A., Bottomly, K. Signals and signs for lymphocyte responses. Cell 76, 275-285 (1994).
37. Huh, J. C. et al. Bidirectional interactions between antigen-bearing respiratory tract dendritic cells (DCs) and T cells precede the late phase reaction in experimental asthma DC activation occurs in the airway mucosa but not in the lung parenchyma. J. Exp. Med. 198, 19-30 (2003).
38. Mellman, I., Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
39. Xiang, J. et al. Antigen-loaded upconversion nanoparticles for dendritic cell stimulation, tracking, and vaccination in dendritic cell-based immunotherapy. ACS Nano 9, 6401-6411 (2015).
40. Wang, C. et al. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv. Mater. 26, 8154-8162 (2014).
41. Carreno, B. M. et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J. Clin. Invest. 123, 3383-3394 (2013).
42. Brunda, M. J. et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178, 1223-1230 (1993).
43. Chu, K. F., Dupuy, D. E. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer 14, 199-208 (2014).
44. Kennedy, J. E. High-intensity focused ultrasound in the treatment of solid tumours. Nat. Rev. Cancer 5, 321-327 (2005).
45. Waitz, R. et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 72, 430-439 (2012).
46. Wang, C. et al. Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis. Adv. Mater. 26, 8154-8162 (2014).
47. Chen, Q., Liang, C., Wang, C., Liu, Z. An imagable and photothermal 'abraxane-like' nanodrug for combination cancer therapy to treat subcutaneous and metastatic breast tumors. Adv. Mater. 27, 903-910 (2015).
48. Chen, Q. et al. An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery. Biomaterials 35, 9355-9362 (2014).
49. Pentcheva-Hoang, T., Corse, E., Allison, J. P. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol. Rev. 229, 67-87 (2009).
50. Curran, M. A., Montalvo, W., Yagita, H., Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275-4280 (2010).
51. Schwartz, R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71, 1065-1068 (1992).
52. Van Elsas, A., Hurwitz, A. A., Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
53. Egen, J. G., Kuhns, M. S., Allison, J. P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
54. Ueda, H. et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423, 506-511 (2003).
55. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
56. Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M. E., Schaeverbeke, T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 13, 211-214 (2015).
57. Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
58. Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. 4, 225-234 (2003).
59. Robinson, H. L., Amara, R. R. T cell vaccines for microbial infections. Nat. Med. 11, S25-S32 (2005).
60. Kaech, S. M., Wherry, E. J., Ahmed, R. Effector and memory T-cell differentiation: Implications for vaccine development. Nat. Rev. Immunol. 2, 251-262 (2002).
61. Schoenborn, J. R., Wilson, C. B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96, 41-101 (2007).
62. Au, L. et al. A quantitative study on the photothermal effect of immuno gold nanocages targeted to breast cancer cells. ACS Nano 2, 1645-1652 (2008).
63. Chen, W. R. et al. Effect of different components of laser immunotherapy in treatment of metastatic tumors in rats. Cancer Res. 62, 4295-4299 (2002).
64. Kasturi, S. P. et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547 (2011).
65. Cheng, J. et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869-876 (2007).
66. Xu, L. et al. Morphologically virus-like fullerenol nanoparticles act as the dual-functional nanoadjuvant for HIV-1 vaccine. Adv. Mater. 25, 5928-5936 (2013).
67. Takahashi, K. et al. Morphological interactions of interdigitating dendritic cells with B and T cells in human mesenteric lymph nodes. Am. J. Pathol. 159, 131-138 (2001).